Q: I believe you have doubts about these two but which one has the sketchy management ?? Could a case be made for holding either or both? Thanx Robbie
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Regarding GUD and ENDP Asked by Serge and others waiting for GUD to make a move. Considering debt load, Enbridge merged with Spectra, Davis and Henderson bought Harland Financial. What happened to ENB share price and where is D&H today. Could Knight be biting off too much as well if they were to move on ENDP considering the debt they would inherit?
Quote: "ENDP has more than $7B in debt and less than $600M in cash flow in the last 12 months. The stock is down 50% in a year. Interest expenses of $488M last year ate up nearly all of its total cash flow. Earnings are lower than they were 8 years ago."
Quote: "ENDP has more than $7B in debt and less than $600M in cash flow in the last 12 months. The stock is down 50% in a year. Interest expenses of $488M last year ate up nearly all of its total cash flow. Earnings are lower than they were 8 years ago."
Q: Would you have a comment on Largo LGO & Fennex Pharma FRX ? RAK
Q: COV seems to be in freefall, down about 50 percent from recent highs. Is there some issue with it or just the market. Are you still comfortable with this in the portfolio?
Q: Do you have any information or an opinion on this US company?
Phil
Phil
Q: What's your view on Bristol Myers Squibb's potential as a longterm investment?
Thanks.
Thanks.
Q: Hi team !
I have been holding pjp-n for almost 3 years and it just keep going down.
I am about 24% in the red. I hold in my TFSA and it is 14% of that account.
Any hope for this ETF to recover soon ? Or would you advise to take my lost and invest in something else with a good growth potential ? I already hold SIS-T
Thanks for your help
Jacques
I have been holding pjp-n for almost 3 years and it just keep going down.
I am about 24% in the red. I hold in my TFSA and it is 14% of that account.
Any hope for this ETF to recover soon ? Or would you advise to take my lost and invest in something else with a good growth potential ? I already hold SIS-T
Thanks for your help
Jacques
Q: Mr. Hodson, could it be that GUD is precluded from buying back ENDO by virtue of a non-compete clause for 3 years ? If so, one would have to abide by that clause. It would no be possible to avoid such clause. Therefore, one would have to await the passage of such time, as this would be binding for both parties. Does that makes sense ?
Q: Hi 5iResearch Team,
I am thinking of taking a position on Nektar Therapeutics (NKTR.O) and would like to get your comments on this company as well as its Q4 earnings released on March 1.
Cheers,
I am thinking of taking a position on Nektar Therapeutics (NKTR.O) and would like to get your comments on this company as well as its Q4 earnings released on March 1.
Cheers,
Q: Is this oversold, possibly some help from short manipulation. Is it probable a deal can be made with PBI-4050 on one indication being IPF.
Q: Is RHT the new PHM? It seems it was heavily promoted, pump-ed up above 2$ , the smart money left, while the dumb money are left to lick their losses. It's basically in free fall every day.
Q: is it a good time to add to rht to bring it back up to a 3 % position
Q: Have held GUD for over 3 years and as a reward I am down aprox, 5% with no divy. to temper my impatience. Am thinking of replacing with BCI or OTEX in my growth portfolio. Would you endorse this move?.....which would have more upside? At what point does 5i run out of patience and throw GUD to the curb?
Q: Hello,
I have another (very) small cap stock question.
Do you have any information on Pascal? Seems interesting from a couple of perspectives.
From their website: "However, Pascal is the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy."
Thanks!
Brian
I have another (very) small cap stock question.
Do you have any information on Pascal? Seems interesting from a couple of perspectives.
From their website: "However, Pascal is the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy."
Thanks!
Brian
Q: Can please give some update after the company has sold its US operations? Will this step will help company to focus on its Canadian operation?
Thanks
Thanks
Q: A BNN guest recently made mention of a European competitor that may soon enter the NA marketplace that could severely impact Savaria's business, to the point where a friend of his considers SIS a short (I think this is also in part due to its valuation). Are you aware of any such threat on the horizon? Does Savaria have any kind of moat or special advantage that might insulate it from new (presumably established & high quality) competition?
Q: Did you glean anything from the company call?
Q: Do you think a buy-out or partnership is likely in the cards for PLI? Would GUD have any interest?
Q: Would this company have technology that would make it attractive to US firms as a take out, it seems to be competing against companies that have market caps in the billions in the US, in this same field.
Thanks
Thanks
Q: I am sure you're getting a lot of questions regarding PLI
Is there any hope recovering our capital?
Is there any hope recovering our capital?